WAM
SVA

Wolverine Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Wolverine Asset Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-99,212
Closed -$699K – 1750
2017
Q3 		$699K Buy
99,212
+20,342
+26% +$139K 0.01% 758
2017
Q2 		$532K Buy
+78,870
New +$432K 0.01% 767

Other funds holding SVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Wolverine Asset Management's SVA Position: Q4 2017 in Review

Wolverine Asset Management sold out of Sinovac Biotech, Ltd (SVA) in Q4 2017, closing a stake of 99,212 shares — an estimated $699K sold.

Wolverine Asset Management first reported a position in SVA in Q2 2017 and held it in 2 quarters. The position peaked at $699K in Q3 2017. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

  • Wolverine Asset Management reported no remaining Sinovac Biotech, Ltd position as of Q4 2017 after selling out during the quarter.
  • Wolverine Asset Management sold 99,212 Sinovac Biotech, Ltd shares in Q4 2017, an estimated $699K.
  • Wolverine Asset Management first reported a position in Sinovac Biotech, Ltd in Q2 2017 and held it in 2 quarters.
  • Wolverine Asset Management's Sinovac Biotech, Ltd position peaked at $699K in Q3 2017.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2017.

Based on Wolverine Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.